🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Abeona Therapeutics Inc. ABEO R2KPHARMA

Healthcare · Biotechnology · United States
https://www.abeonatherapeutics.com
Company Profile ↓
$4.40
-32.93% 1Y
Mkt Cap$251.61M
P/E-3.73
P/B2.21
52W High$7.46
52W Low$4.17
Book Value$2.24
EPS (TTM)$-1.18

Company Overview

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 39.5%.

Consistent Profit Growth

Net profit has compounded at 93.1% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 60.3% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.16.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue +2745.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 60.3%, profit CAGR 93.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:60.26%
1 Year:2,745.00%

Compounded Profit Growth

5 Years:93.11%
1 Year:-

Stock Price Performance

1 Year:-32.93%
6 Months:-18.37%
3 Months:-28.22%
1 Month:-18.97%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 7% of range
$4.17 $7.46
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • Death Cross3d ago
  • RSI (14)33.33 · Neutral
Price Performance
1M-18.97%
3M-28.22%
6M-18.37%
1Y-32.93%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 39.5%.
  • Compounding revenue at 60.3% over 5 years.
  • Profit CAGR of 93.1% over 5 years.

CONS

  • Trading 41.0% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-3.73
Industry PE
25.45
Forward P/E
-21.20
PEG Ratio
-
Book Value
$2.24
Price to Book
2.21
P/S
11.07
EV/EBITDA
-2.02
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
60.26%
Profit 5Y
93.11%
Revenue (YoY)
2,745.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
39.49%
ROE
-43.13%
ROA
-24.55%
Profit Margin
-
Op Margin
-
Gross Margin
-39.90%
EPS (Latest Qtr)
$-0.30
EPS (TTM)
$-1.18

Balance Sheet & Liquidity

Debt/Equity
0.16
Quick Ratio
6.32
Current Ratio
6.63
Debt
$19.87M
Total Assets
$198.49M
Current Assets
$182.99M
Working Capital
$175.34M

Ownership

Promoter Holding
10.96%
Chg in Prom Hold
-0.35%
FII / Inst Holding
74.90%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
$251.61M
Total Revenue (TTM)
$25.52M
EBITDA
$-80.79M
Free Cash Flow
$-73.40M
Operating Cash Flow
$-76.44M
Shares Outstanding
57.18M
Gross Margin
-39.90%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ABEO Abeona Therapeutics Inc. R2KPHARMA 4.40 -3.73 $251.61M 0.00% 39.49% -43.13% 60.26% 93.11%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------------1.71M-------7.00M---346.00K1.00M--3.50M-----0400.00K05.42M8.72M
Cost of Revenue -----------------------------------0100.00K488.00K2.84M2.70M
Gross Profit -----------------------------------0300.00K-488.00K2.58M6.02M
Operating Expenses -----------------------------------19.73M23.09M23.53M25.49M29.06M
Operating Income -633.00K-2.00M-4.13M-6.16M-6.16M-6.71M-5.17M-5.28M-8.44M-5.36M-8.75M-10.68M-12.56M-16.92M-18.01M-19.05M-23.98M-17.65M-16.41M-48.21M-12.48M-6.25M-14.60M-13.71M-14.87M-20.59M-8.01M-9.38M-12.04M-10.55M-11.33M-14.33M-17.86M---19.73M-22.79M-24.02M-22.91M-23.03M
EBITDA ------------------------------------10.22M126.07M-18.57M-18.70M-15.37M
Interest Expense -----------------------------------998.00K957.00K901.00K884.00K830.00K
Pretax Income ------------------------------------12.03M124.34M-20.36M-20.68M-17.07M
Tax Provision -----------------------------------015.51M-15.20M-215.00K2.00K
Net Income -1.47M-2.00M-4.11M-6.07M-5.54M-6.70M-2.62M-5.25M-8.28M-5.34M-8.45M-10.53M-12.24M-16.42M-17.48M-18.55M-23.92M-17.37M-16.43M-48.16M-13.01M-7.24M-16.00M-15.21M-7.04M-22.04M-4.10M-6.43M-9.11M-16.65M-11.84M-31.58M7.41M---12.03M108.83M-5.16M-20.46M-17.07M
Diluted EPS -4.15-------------------------1.36-1.00-0.54-0.92-0.48-1.16-0.26-0.63--0.241.71-0.10--0.30
R&D Expense 73.00K453.00K610.00K1.58M1.85M3.02M2.75M2.20M5.81M3.28M5.71M8.16M7.92M13.15M9.47M11.74M16.31M10.92M9.61M6.82M6.11M7.97M8.32M8.53M9.06M10.54M6.66M5.49M8.04M8.52M7.15M7.21M9.22M8.94M-9.94M5.94M4.22M-9.55M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 481.00K1.84M4.40M2.04M925.00K1.04M889.00K837.00K3.00M-10.00M-1.41M3.50M05.82M
Cost of Revenue ------------450.00K1.60M03.42M
Gross Profit ------------964.00K1.90M02.40M
Operating Expenses ------------46.22M50.09M64.21M91.84M
Operating Income -7.76M-7.88M-4.32M-3.80M-3.13M-18.55M-23.88M-27.84M-58.17M-77.09M-81.42M--45.26M-48.20M-64.21M-89.45M
EBITDA -------------34.38M-50.57M-56.62M78.59M
Interest Expense ------------736.00K418.00K4.21M3.74M
Pretax Income -------------39.70M-54.19M-63.73M71.28M
Tax Provision --------------0100.00K
Net Income -7.54M-2.53M-10.53M4.45M-26.78M-14.53M-21.87M-27.32M-56.67M-76.28M-84.23M--39.70M-54.19M-63.73M71.18M
Diluted EPS ---0.523.04-15.26--------5.53-2.53-1.551.01
R&D Expense 3.35M3.58M2.01M884.00K333.00K4.71M10.65M16.99M38.70M48.57M30.14M38.73M28.96M31.09M34.36M26.81M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Jan 2018Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -8.77M3.79M1.73M613.00K16.58M80.06M111.06M178.77M-174.40M223.38M151.20M-64.21M64.00M108.93M219.57M
Current Assets --------------53.10M55.74M100.85M204.91M
Cash & Equivalents 607.00K7.03M2.46M396.00K424.00K11.52M40.14M69.14M137.75M-18.75M129.26M12.60M-14.22M14.47M23.36M78.44M
Inventory ----------------05.49M
Receivables -------------3.00M0-06.15M
Total Liabilities -29.57M21.39M18.81M15.39M11.77M12.33M11.96M8.67M2.39M40.35M44.95M48.65M-37.45M49.18M64.90M60.35M
Current Liabilities -14.26M12.19M6.63M8.96M2.90M1.48M8.30M5.61M2.39M20.35M38.70M41.96M-7.78M13.42M16.59M29.57M
Long Term Debt ----------------13.04M7.81M
Total Debt --------------7.63M5.40M23.05M24.97M
Total Equity --20.80M-17.61M-17.08M-14.78M4.82M67.72M99.10M170.10M6.30M134.04M178.43M102.55M-26.76M14.83M44.03M159.22M
Shares Outstanding --------------17.72M26.52M45.64M55.04M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -6.86M-7.61M-3.96M1.00K---13.01M-22.66M-39.11M-62.82M-35.02M--43.48M-37.01M-56.02M-76.33M
Investing Cash Flow -7.00K-40.00K-13.00K-2.00K---519.00K-860.00K-85.09M59.98M-83.71M--23.96M208.00K-39.24M105.03M
Financing Cash Flow 13.29M3.08M1.90M29.00K--42.54M92.40M5.48M113.90M1.94M-43.17M37.06M104.14M26.04M
Capital Expenditure -7.00K-40.00K-13.00K-2.00K-0-308.00K-519.00K-860.00K-9.24M-6.31M-1.34M--130.00K-331.00K-2.45M-7.97M
Free Cash Flow -6.87M-7.65M-3.97M-1.00K---13.53M-23.52M-48.35M-69.13M-36.35M--43.61M-37.34M-58.46M-84.30M
Net Change in Cash -------------24.27M256.00K8.88M54.74M

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------------68.2%54.1%-41.2%
Operating Margin % -1,612.7%-428.3%-98.0%-186.3%-338.5%-1,783.3%-2,686.3%-3,325.7%-1,940.2%--814.2%--3,200.6%-1,377.1%--1,536.9%
Net Margin % -1,566.9%-137.7%-239.1%217.9%-2,894.9%-1,396.7%-2,460.4%-3,263.9%-1,890.3%--842.3%--2,807.4%-1,548.2%-1,223.1%
ROE % 36.2%14.4%61.7%-30.1%-556.0%-21.4%-22.1%-16.1%-42.3%-42.8%-82.1%--148.3%-365.5%-144.7%44.7%
ROCE % 141.4%93.7%88.1%45.6%-22.9%-23.6%-23.2%-16.1%-37.8%-41.7%-74.5%--80.2%-95.3%-69.5%-47.1%

Shareholding Pattern

Insiders
10.96%
Institutions
74.90%
Public Float
84.12%

Top Institutional Holders

#Holder% HeldSharesValue
1 Nantahala Capital Management, LLC 8.98% 5.14M $25.37M
2 Blackrock Inc. 5.86% 3.35M $16.56M
3 Cable Car Capital, LP 5.26% 3.01M $14.86M
4 AIGH Capital Management LLC 5.22% 2.99M $14.76M
5 Vanguard Capital Management LLC 3.87% 2.21M $10.92M
6 OneDigital Investment Advisors LLC 2.89% 1.65M $8.17M
7 AWM Investment Company, Inc. 2.60% 1.49M $7.34M
8 Geode Capital Management, LLC 2.21% 1.26M $6.23M
9 Kennedy Capital Management, LLC 2.17% 1.24M $6.13M
10 Goldman Sachs Group Inc 2.14% 1.22M $6.05M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ABEO

Yahoo Finance Fri, 02 Oct 2026

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance wit…

Yahoo Finance ue, 22 Sep 2026

Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright

Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual confe…

Yahoo Finance ue, 22 Sep 2026

Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum

Abeona Therapeutics (NASDAQ:ABEO) executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare C…

Yahoo Finance Fri, 18 Sep 2026

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts - - Ultragenyx successfully brought a life-changing therapy across the finish line for MPS …

Yahoo Finance hu, 17 Sep 2026

ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells

Abeona stands to collect mid-single-digit royalties on sales of Ultragenyx’s Fayuvi plus up to $30 million in commercial milestone payments as part of a licensing deal.

Yahoo Finance Wed, 16 Sep 2026

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of Un…

ABEO — Frequently Asked Questions

What is the current share price of Abeona Therapeutics Inc. (ABEO)?

As of 2026-10-23 16:27 PDT, Abeona Therapeutics Inc. (ABEO) trades at $4.40 on NasdaqCM. Its 52-week range is $4.17 to $7.46.

What is the market capitalisation of ABEO?

Abeona Therapeutics Inc. (ABEO) has a market capitalisation of $251.61M on NasdaqCM.

What is the P/E ratio of ABEO?

ABEO trades at a trailing price-to-earnings (P/E) ratio of -3.73. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.21.

What is the return on equity (ROE) of ABEO?

ABEO has a return on equity (ROE) of -43.13%. Its return on capital employed (ROCE) is 39.49%.

Is ABEO a good stock to buy?

This page provides a data-driven analysis of Abeona Therapeutics Inc. (ABEO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space